# Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

> **NCT00452400** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 409 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive
- Asthma

## Interventions

- **DRUG:** BI 1744CL

## Key facts

- **NCT ID:** NCT00452400
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-01
- **Final completion:** —
- **Target enrollment:** 409 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00452400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00452400, "Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT00452400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*